Lymphoma

Collectively, these findings suggest that IRAIN may participate in the regulation of proliferation, apoptosis, and cell cycle progression in MCL cells, potentially through modulation of LSD1. These results provide preliminary experimental evidence for further understanding the potential biological function of IRAIN in MCL.

P2, N=80, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting

P1, N=19, Recruiting, University Health Network, Toronto | Trial completion date: May 2026 --> Jun 2028 | Trial primary completion date: Mar 2026 --> Jun 2028

LN metastasis is associated with a remodelled systemic immunity, enriches immunosuppressive neutrophils and TandNK cells and activates LGALS9‒HAVCR2 signalling. These findings reveal immune signatures associated with LN metastasis status and identify candidate biomarkers and therapeutic targets warranting further validation.

CGGD primarily intervenes in STC combined with depression through pathways including the phosphatidylinositol 3-kinase-Akt signaling pathway, the mitogen-activated protein kinase signaling pathway, and the apoptosis pathway. Through an integrated network pharmacology approach, this study describes the synergistic effects of multiple ingredients, targets, and pathways of CGGD in the treatment of STC combined with depression.

Notably, the E3 ubiquitin ligase TRIM37 (tripartite motif containing 37) facilitates the polyubiquitination of lysine residues at position 116 of PFN1, which serves as a critical recognition motif for the cargo receptor SQSTM1/p62 (sequestosome 1), which is pivotal for the subsequent autophagic degradation of ORF44. Overall, our findings revealed a previously uncharacterized antiviral function of PFN1, highlighting its potential as a novel therapeutic avenue for the treatment of KSHV-associated malignancies.

FTO suppresses BCL6 via m6 A demethylation, inhibiting ferroptosis to promote GC progression. The FTO/BCL6 axis is a potential therapeutic target for GC.

LIEE exhibits significant anti-osteoporotic effects through a multi-targeted mechanism involving modulation of ER/OPG/RANKL signalling, suppression of inflammation and oxidative stress, and regulation of key molecular targets. These outcomes propose that LIEE could help as a capable phytotherapeutic candidate for the management of postmenopausal osteoporosis and warrant more clinical exploration.

P2, N=9, Active, not recruiting, City of Hope Medical Center | Recruiting --> Active, not recruiting | N=20 --> 9

P2, N=76, Recruiting, University Health Network, Toronto | Trial completion date: Dec 2027 --> Dec 2029 | Trial primary completion date: Apr 2026 --> Apr 2029

Synergistic gene regulation was introduced by co-delivering BCL2 antisense oligonucleotide and BSeTPE-Pt-ac with amphiphilic tumor-targeting polymers, which effectively silenced BCL2 expression, overcame thermal resistance, and thus maximized the chemo-PTT efficacy of BSeTPE-Pt-ac. Our work elucidates the rational design of a multifunctional platinum(II) agent by effectively integrating key anticancer functionalities, offering valuable insights into the development of advanced multifunctional agents.

P2, N=150, Recruiting, University Hospital, Clermont-Ferrand | Trial completion date: Dec 2027 --> May 2030 | Trial primary completion date: Oct 2026 --> May 2030